The study’s objective is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy (PDT) treatments with Levulan Kerastick in combination with BLU-U brand blue light versus use of the BLU-U alone in patients with moderate to severe facial acne vulgaris. This trial will evaluate the incremental advantage of adding Levulan to Dusa’s already FDA-cleared BLU-U blue light therapy when treating acne.
Bob Doman, president and CEO of Dusa, said: “Once the initial results are available, which we expect this fall, company will decide on the next steps needed to develop this indication for potential FDA approval.”